Radiological evolution of pituitary hyperplasia in primary hypothyroidism and its differentiation from nonfunctioning pituitary adenoma coexisting with primary hypothyroidism
- PMID: 39117777
- DOI: 10.1007/s12020-024-03983-1
Radiological evolution of pituitary hyperplasia in primary hypothyroidism and its differentiation from nonfunctioning pituitary adenoma coexisting with primary hypothyroidism
Abstract
Purpose: In a patient with elevated thyroid stimulating hormone (TSH, >50 µIU/ml) with sellar mass, it is crucial to differentiate isolated pituitary hyperplasia (IPH) from primary hypothyroidism coexisting with nonfunctioning pituitary adenoma (PHCNFPA) pre-operatively to avoid unwarranted surgery in the former condition. Here, we describe patients having pituitary mass/enlargement with markedly elevated TSH (>50 µIU/ml) and attempt to find the differentiating features between IPH and PHCNFPA.
Methods: This is a retrospective study conducted at a tertiary care center. Case records of patients presenting between January 2020 and December 2022 with elevated TSH (>50 µIU/ml) for whom magnetic resonance imaging (MRI) of the sella was available were reviewed. Demographic details, symptomatology, clinical examination findings, thyroid function tests, data on pituitary hormonal excess and deficiencies, MRI findings, and details regarding levothyroxine supplementation were noted. Based on the final diagnosis, the patients were categorized into two groups: PHCNFPA and IPH.
Results: Five and 11 patients were diagnosed with PHCNFPA and IPH, respectively. The median (IQR) age at presentation of patients with PHCNFPA was significantly higher than that of IPH patients [37 (28-60.5) vs. 21 (10-21.5) years, p: 0.002]. A longer duration of hypothyroid symptoms was noted in the IPH group whereas visual field defects and corticotropin deficiency were more frequent and the pituitary lesion size was greater in PHCNFPA. Thyroid function tests were not different between the two groups. The pituitary enlargement in IPH was initially an increase in pituitary height that progressed to symmetrical nipple-, dome- or tent-shaped enlargement. Besides this characteristic enlargement pattern, isointense appearance on T1-weighted and T2-weighted images, homogeneous contrast enhancement, and prompt regression of pituitary lesion with levothyroxine replacement were characteristic of IPH whereas heterogeneous enhancement, cystic/hemorrhagic change, and ≥Knosp III invasion were characteristic of PHCNFPA. Peripheral rim enhancement and Knosp I-II parasellar extension were not uncommon in patients with IPH and did not distinguish it from PHCNFPA.
Conclusions: The present study reports the radiological evolution of IPH and a unique series of PHCNFPA along with the distinguishing characteristics between them.
Keywords: Pituitary adenoma; Pituitary hyperplasia; Primary hypothyroidism with nonfunctioning pituitary adenoma; Thyrotrope hyperplasia.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Pituitary enlargement in patients with primary hypothyroidism.Endocr Pract. 2006 Jan-Feb;12(1):29-34. doi: 10.4158/EP.12.1.29. Endocr Pract. 2006. PMID: 16524860
-
[A case of pseudo-TSH.PRL-producing pituitary adenoma with secondary hypothyroidism].No To Shinkei. 1991 Feb;43(2):187-91. No To Shinkei. 1991. PMID: 1873088 Japanese.
-
MRI-demonstrable regression of a pituitary mass in a case of primary hypothyroidism after a week of acute thyroid hormone therapy.J Clin Endocrinol Metab. 1997 Mar;82(3):808-11. doi: 10.1210/jcem.82.3.3796. J Clin Endocrinol Metab. 1997. PMID: 9062487
-
[Thyrotropin-producing adenomas and thyrotropic hyperplasia (clinical case reports and the review of the literature)].Zh Vopr Neirokhir Im N N Burdenko. 2016;80(3):82-90. doi: 10.17116/neiro201680382-90. Zh Vopr Neirokhir Im N N Burdenko. 2016. PMID: 28635844 Review. Russian.
-
Suprasellar pituitary adenomas: a 10-year experience in a single tertiary medical center and a literature review.Pituitary. 2020 Aug;23(4):367-380. doi: 10.1007/s11102-020-01043-1. Pituitary. 2020. PMID: 32378170 Review.
References
-
- A.F. Daly, A. Beckers, The epidemiology of pituitary adenomas. Endocrinol. Metab. Clin. North Am. 49, 347–355 (2020). https://doi.org/10.1016/j.ecl.2020.04.002 . - DOI - PubMed
-
- M. Fleseriu, N. Karavitaki, Non-functioning pituitary adenomas, not all the same and certainly not boring! Pituitary 21, 109–110 (2018). https://doi.org/10.1007/s11102-018-0875-5 . - DOI
-
- S.M. De Sousa, P. Earls, A.I. McCormack, Pituitary hyperplasia: case series and literature review of an under-recognised and heterogeneous condition. Endocrinol. Diab. Metab. Case Rep. 2015, 150017 (2015). https://doi.org/10.1530/EDM-15-0017 . - DOI
-
- B.W. Scheithauer, K. Kovacs, R.V. Randall, N. Ryan, Pituitary gland in hypothyroidism. Histologic and immunocytologic study. Arch. Pathol. Lab Med. 109, 499–504 (1985). - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical